Cumberland Pharmaceuticals Inc (CPIX) Stock Price & Analysis
Cumberland Pharmaceuticals Inc (CPIX) rose 0.59% to USD 6.79 as of September 8, 2026 at 09:05 UTC, according to Nexqual real-time market data.
CPIX last closed at USD 6.79; the session ranged USD 6.65–6.9 on volume of 14,077 shares. Market capitalization is —, with a 52-week range of USD 1.85–9.28 (NMS). Source: Nexqual, September 8, 2026 at 09:05 UTC.
Key Statistics (as of September 8, 2026 at 09:05 UTC)
| Price | USD 6.79 |
|---|---|
| Change | ▲ 0.59% (up) |
| Previous Close | USD 6.79 |
| Open | USD 6.79 |
| Day Range | USD 6.65 – 6.9 |
| 52-Week Range | USD 1.85 – 9.28 |
| Volume | 14,077 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (CPIX)
Nexqual's technical model rates CPIX "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.08 (neutral) |
| vs SMA50 | Below (USD 7.22) |
| MACD | -0.09 (negative) |
From Cumberland Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center.
- In November 2024, the FDA also approved a supplemental New Drug Application for Acetadote, adding a simplified dosing regimen for the product prescribing information.
- This team has successfully devised regulatory and clinical strategies for our product portfolio, including obtaining FDA approvals for Acetadote and Caldolor brands.
- The court also granted a permanent injunction preventing challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of one of Cumberland's patents in August 2025.
Partnerships
- We also entered into a strategic alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization.
- In August 2020, we entered into an agreement with WinHealth Investment (Singapore) Ltd. creating WHC Biopharmaceuticals, Pte.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 20% |
| ISPC | iSpecimen Inc. | USD 1.54 | ▲ 3.36% |
| BFRI | Biofrontera Inc. | USD 1.61 | ▲ 5.92% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▲ 0% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.54 | ▼ 4.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:05 UTC. This page is informational and not investment advice.